{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:35:42Z","timestamp":1789907742607,"version":"4.0.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006413","name":"Ariad Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1053\/j.ackd.2019.08.009","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T23:13:11Z","timestamp":1573686791000},"page":"393-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Membranous Lupus Nephritis: A Clinical Review"],"prefix":"10.1053","volume":"26","author":[{"given":"Salem","family":"Almaani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir V.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.ackd.2019.08.009_bib1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.05780616","article-title":"Update on lupus nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.009_bib2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00005792-197809000-00001","article-title":"Renal involvement in systemic lupus erythematosus (SLE): a study of 56 patients emphasizing histologic classification","volume":"57","author":"Appel","year":"1978","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.009_bib3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2019.08.009_bib4","series-title":"Renal Disease: Classification and Atlas of Glomerular Disease","author":"Churg","year":"1982"},{"key":"10.1053\/j.ackd.2019.08.009_bib5","series-title":"Renal Disease: Classification and Atlas of Glomerular Diseases","author":"Churg","year":"1995"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.009_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1681\/ASN.V72299","article-title":"Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group","volume":"7","author":"Sloan","year":"1996","journal-title":"J Am Soc Nephrol"},{"issue":"2 Suppl","key":"10.1053\/j.ackd.2019.08.009_bib7","first-page":"221","article-title":"KDIGO Clinical Practice Guidelines: Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.009_bib8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","article-title":"Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy","volume":"20","author":"Austin","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.009_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ki.2009.412","article-title":"Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis","volume":"77","author":"Radhakrishnan","year":"2010","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.009_bib10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3899\/jrheum.080335","article-title":"Current therapies for lupus nephritis in an ethnically heterogeneous cohort","volume":"36","author":"Rivera","year":"2009","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.009_bib12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1053\/j.ajkd.2011.10.044","article-title":"Antibodies to M-type phospholipase A2 receptor (PLA2R) and membranous lupus nephritis","volume":"59","author":"Gunnarsson","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.009_bib13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/0961203319828521","article-title":"Antibodies to M-type phospholipase A2 receptor (PLA2R) in membranous lupus nephritis","volume":"28","author":"Garcia-Vives","year":"2019","journal-title":"Lupus"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.009_bib14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.009_bib15","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1046\/j.1523-1755.1998.00874.x","article-title":"Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. \u201cGruppo Italiano di Studi Epidemiologici in Nefrologia\u201d (GISEN)","volume":"53","author":"Ruggenenti","year":"1998","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.009_bib16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.009_bib17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0272-6386(96)90512-0","article-title":"The role of proteinuria in the progression of chronic renal failure","volume":"27","author":"Burton","year":"1996","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ackd.2019.08.009_bib18","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1097\/01.ASN.0000100145.27188.33","article-title":"Management of glomerular proteinuria: a commentary","volume":"14","author":"Wilmer","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib19","doi-asserted-by":"crossref","first-page":"e000123","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.009_bib20","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort","volume":"67","author":"Dall'Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.009_bib21","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.2215\/CJN.01480308","article-title":"D-dimer level and the risk for thrombosis in systemic lupus erythematosus","volume":"3","author":"Wu","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.009_bib22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.7326\/0003-4819-142-5-200503010-00009","article-title":"The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study","volume":"142","author":"Sarnak","year":"2005","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.009_bib23","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive blood-pressure control in hypertensive chronic kidney disease","volume":"363","author":"Appel","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.009_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000093833","article-title":"An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease","volume":"26","author":"Jones-Burton","year":"2006","journal-title":"Am J Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.009_bib25","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/nu10060732","article-title":"Dietary salt restriction in chronic kidney disease: a meta-analysis of randomized clinical trials","volume":"10","author":"Garofalo","year":"2018","journal-title":"Nutrients"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.009_bib26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ki.1989.190","article-title":"Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril","volume":"36","author":"Heeg","year":"1989","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.009_bib27","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan","volume":"19","author":"Vogt","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.009_bib28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/j.1523-1755.2004.00462.x","article-title":"An ACE inhibitor reduces Th2 cytokines and TGF-\u03b21 and TGF-\u03b22 isoforms in murine lupus nephritis","volume":"65","author":"De Albuquerque","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib29","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2353","article-title":"The role of aldosterone blockade in murine lupus nephritis","volume":"10","author":"Monrad","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.009_bib30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3899\/jrheum.170561","article-title":"Early renin-angiotensin system blockade improved short-term and longterm renal outcomes in systemic lupus erythematosus patients with antiphospholipid-associated nephropathy","volume":"45","author":"Yue","year":"2018","journal-title":"J Rheumatol"},{"issue":"15","key":"10.1053\/j.ackd.2019.08.009_bib31","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.ackd.2019.08.009_bib32","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.009_bib33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/ATVBAHA.113.302854","article-title":"Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors","volume":"34","author":"Pruthi","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.009_bib34","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1681\/ASN.2007101079","article-title":"The aggravating mechanisms of aldosterone on kidney fibrosis","volume":"19","author":"Remuzzi","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.009_bib35","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and\u00a0renal\u00a0inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.009_bib36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/j.ajkd.2011.03.029","article-title":"Aldosterone-induced fibrosis in the kidney: questions and controversies","volume":"58","author":"Brem","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.009_bib37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2215\/CJN.00120106","article-title":"Aldosterone antagonism in chronic kidney disease","volume":"1","author":"Ponda","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneph.2017.155","article-title":"Dyslipidaemia in nephrotic syndrome: mechanisms and treatment","volume":"14","author":"Agrawal","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"15-16","key":"10.1053\/j.ackd.2019.08.009_bib40","first-page":"716","article-title":"Role of lipids in the progression of renal disease in systemic lupus erythematosus patients","volume":"112","author":"Luzar","year":"2000","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.009_bib41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/157340308784245775","article-title":"Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors","volume":"4","author":"Zeller","year":"2008","journal-title":"Curr Cardiol Rev"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2015.08.030","article-title":"Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study","volume":"243","author":"Yu","year":"2015","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.009_bib43","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.24379","article-title":"Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study","volume":"60","author":"Norby","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.009_bib44","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/ar3402","article-title":"Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study","volume":"13","author":"Plazak","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.009_bib45","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/acr.20440","article-title":"Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Mok","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.009_bib46","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2010.136762","article-title":"Lupus atherosclerosis prevention study (LAPS)","volume":"70","author":"Petri","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.009_bib47","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1053\/j.ackd.2019.08.009_bib48","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrrheum.2012.106","article-title":"New\u00a0insights into mechanisms of therapeutic effects of antimalarial\u00a0agents in SLE","volume":"8","author":"Wallace","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.009_bib49","first-page":"375","article-title":"The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus","volume":"21","author":"Wallace","year":"1994","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.009_bib50","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1191\/0961203306lu2299oa","article-title":"Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients","volume":"15","author":"Wozniacka","year":"2006","journal-title":"Lupus"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.009_bib51","first-page":"1124","article-title":"The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus","volume":"159","author":"Wozniacka","year":"2008","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.009_bib52","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1002\/art.22156","article-title":"Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus","volume":"54","author":"Costedoat-Chalumeau","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib53","doi-asserted-by":"crossref","first-page":"e000089","DOI":"10.1136\/lupus-2015-000089","article-title":"Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome","volume":"2","author":"Dall'Era","year":"2015","journal-title":"Lupus Sci Med"},{"issue":"01","key":"10.1053\/j.ackd.2019.08.009_bib54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0961203307083443","article-title":"Long-term outcome of Chinese patients with membranous lupus nephropathy","volume":"17","author":"Sun","year":"2008","journal-title":"Lupus"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.009_bib56","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/ndt\/17.10.1771","article-title":"Factors affecting outcome and prognosis in membranous lupus nephropathy","volume":"17","author":"Mercadal","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.009_bib57","first-page":"175","article-title":"Lupus membranous nephropathy: long-term outcome","volume":"39","author":"Pasquali","year":"1993","journal-title":"Clin Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.009_bib58","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ki.2013.476","article-title":"Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy","volume":"85","author":"Lee","year":"2014","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.009_bib59","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.107.716951","article-title":"High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome","volume":"117","author":"Mahmoodi","year":"2008","journal-title":"Circulation"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.009_bib60","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2013.10.014","article-title":"Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis","volume":"13","author":"Arnaud","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.009_bib61","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.autrev.2014.10.019","article-title":"Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies","volume":"14","author":"Arnaud","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1053\/j.ackd.2019.08.009_bib62","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals","volume":"56","author":"Erkan","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1053\/j.ackd.2019.08.009_bib63","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.3324\/haematol.2017.185132","article-title":"Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban","volume":"103","author":"Martinelli","year":"2018","journal-title":"Haematologica"},{"issue":"11","key":"10.1053\/j.ackd.2019.08.009_bib64","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"issue":"24","key":"10.1053\/j.ackd.2019.08.009_bib65","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2019.08.009_bib66","doi-asserted-by":"crossref","first-page":"e4944","DOI":"10.1136\/bmj.e4944","article-title":"Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis","volume":"345","author":"Mantha","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2015.318","article-title":"Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis","volume":"89","author":"Rathi","year":"2016","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.009_bib71","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1440-1797.2012.01574.x","article-title":"Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome","volume":"17","author":"Yap","year":"2012","journal-title":"Nephrology"},{"issue":"11","key":"10.1053\/j.ackd.2019.08.009_bib72","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/rheumatology\/ken335","article-title":"Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis","volume":"47","author":"Kwan","year":"2008","journal-title":"Rheumatology"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.009_bib73","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1053\/j.ajkd.2003.10.029","article-title":"Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial","volume":"43","author":"Mok","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.009_bib74","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1111\/j.1523-1755.2004.66030.x","article-title":"Mycophenolate therapy of SLE membranous nephropathy","volume":"66","author":"Spetie","year":"2004","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.ackd.2019.08.009_bib75","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1191\/096120399678840837","article-title":"Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression","volume":"8","author":"Chan","year":"1999","journal-title":"Lupus"},{"issue":"9","key":"10.1053\/j.ackd.2019.08.009_bib76","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s10067-016-3366-y","article-title":"Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population","volume":"35","author":"Mejia-Vilet","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.009_bib77","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"27","key":"10.1053\/j.ackd.2019.08.009_bib78","doi-asserted-by":"crossref","first-page":"e7429","DOI":"10.1097\/MD.0000000000007429","article-title":"Rituximab alone as induction therapy for membranous lupus nephritis: a multicenter retrospective study","volume":"96","author":"Chavarot","year":"2017","journal-title":"Medicine"},{"issue":"7","key":"10.1053\/j.ackd.2019.08.009_bib79","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00467-010-1469-2","article-title":"Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies","volume":"25","author":"Bensman","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib80","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0961203306073167","article-title":"A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade","volume":"16","author":"Tse","year":"2007","journal-title":"Lupus"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.009_bib81","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/ajkd.1998.v31.pm9531186","article-title":"Treatment of membranous lupus nephritis","volume":"31","author":"Moroni","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.009_bib82","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/s10165-009-0218-5","article-title":"Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study","volume":"19","author":"Miyasaka","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib83","first-page":"6","article-title":"Tacrolimus is effective for lupus nephritis patients with persistent proteinuria","volume":"28","author":"Uchino","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.009_bib84","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2310\/JIM.0b013e318204c965","article-title":"Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis","volume":"59","author":"Swan","year":"2011","journal-title":"J Investig Med"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.009_bib85","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1093\/ndt\/gfs073","article-title":"Survival analysis and causes of mortality in patients with lupus nephritis","volume":"27","author":"Tang","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1053\/j.ackd.2019.08.009_bib86","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1093\/ndt\/gfs122","article-title":"Outcome of patients with membranous lupus nephritis in Cape\u00a0Town South Africa","volume":"27","author":"Okpechi","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.009_bib87","first-page":"186","article-title":"Lupus membranous glomerulonephritis: different prognostic subgroups obscured by imprecise histologic classifications","volume":"3","author":"Adler","year":"1990","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.009_bib88","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.semarthrit.2011.08.002","article-title":"Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients","volume":"41","author":"Moroni","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1053\/j.ackd.2019.08.009_bib89","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1093\/ndt\/gfp359","article-title":"The clinical relevance of a repeat biopsy in lupus nephritis flares","volume":"24","author":"Daleboudt","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.009_bib90","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0272-6386(99)70082-X","article-title":"Clinical and prognostic value of serial renal biopsies in lupus nephritis","volume":"34","author":"Moroni","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ackd.2019.08.009_bib91","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1093\/ndt\/gft272","article-title":"The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients","volume":"28","author":"Pagni","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.009_bib92","doi-asserted-by":"crossref","first-page":"e000004","DOI":"10.1136\/lupus-2013-000004","article-title":"Value of repeat biopsy in lupus nephritis flares","volume":"1","author":"Greloni","year":"2014","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.009_bib93","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J Am Soc Nephrol"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519301491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519301491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:02:02Z","timestamp":1761548522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559519301491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1548559519301491"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2019.08.009","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Membranous Lupus Nephritis: A Clinical Review","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2019.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}